HCC STUDY

HPB B

HCC Study Group

Study Group Leaders

Albert Chan (Queen Mary Hospital, Hong Kong)

Parissa Tabrizian (MT. Sinai New York, USA)

TITLE: Curative resection following neoadjuvant therapy in patients with high-risk HCC features

INTRODUCTION

Recurrence following liver resection in patients with high-risk features remains high. In these circumstances treatment with neoadjuvant (TACE/Y90/Immunotherapy/SBRT/ablation) may allow downstaging and improve outcome.

OBJECTIVES

Primary objective

• Overall and disease free survival in patients undergoing neoadjuvant therapy (TACE/Y90/immunotherapy/SBRT/ablation) following resection in borderline resectable cases vs. resection upfront.

Secondary objectives

• Time to recurrence

STUDY DESIGN: Retrospective

PARTICIPANTS: International multi-center

ELIGIBILITY CRITERIA:

Inclusion criteria/ defining borderline resectable cases:

Resection candidates:

• MELD <15

• Child Pugh A or better liver function

• Unilobar disease

• No portal hypertension

• No extrahepatic disease

High-risk features/Borderline cases:

• AFP >400 ng/mL

• Infiltrative tumor

• Macrovascular invasion (segmental or lobar ipsilateral PVT or hepatic venous involvement)

• Multifocal disease

• Presence of satellite lesions

 

Participate button